A Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Treating Interstitial Lung Disease Associated With the Anti-synthetase Syndrome

Next Previous
Trial Profile

A Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Treating Interstitial Lung Disease Associated With the Anti-synthetase Syndrome

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Abatacept (Primary)
  • Indications Interstitial lung diseases; Myositis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ATtackMy-ILD

    • Most Recent Events

    • 09 Oct 2017 Status changed from not yet recruiting to recruiting.
    • 08 Sep 2017 Planned initiation date changed from 30 Aug 2017 to 30 Sep 2017.
    • 07 Aug 2017 Planned initiation date changed from 1 Aug 2017 to 30 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top